600420 国药现代
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入5,585,316-19.29%9,363,07410,937,52512,069,93012,959,321
减:营业总成本5,151,130-12.10%8,138,4769,209,24410,999,67412,043,987
    其中:营业成本3,960,800-14.20%6,327,0736,645,2147,444,0138,024,563
               财务费用12,714-132.48%(39,176)(88,680)(75,492)(46,129)
               资产减值损失(47,610)-19.08%(124,086)(168,499)(79,105)(46,704)
公允价值变动收益------------
投资收益72,7816.58%133,89964,10627,4542,343
    其中:对联营企业和合营企业的投资收益16,983-23.13%24,40213,7515,6044,949
营业利润531,315-51.86%1,313,5151,751,9241,081,627966,135
利润总额523,587-53.06%1,327,5851,673,0541,096,560984,120
减:所得税费用93,044-48.95%185,419340,974131,949116,635
净利润430,543-53.87%1,142,1661,332,080964,611867,485
减:非控股权益119,562-9.46%200,564248,457272,730239,690
股东净利润310,981-61.18%941,6021,083,623691,880627,795

市场价值指针
每股收益 (元) *0.232-61.18%0.7020.8080.5430.611
每股派息 (元) *0.050-50.00%0.3000.3000.1000.100
每股净资产 (元) *10.2560.85%10.2749.8459.2379.781
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容